4BB
NEUTRAL4basebio Announces Employee Incentive Plan and Share Issuance
The biotechnology company has announced an employee long-term incentive plan and the issuance of new shares, but the financial details and business impact are unclear.
4basebio
885.00GBX
0.00%
Market Cap
137.04M
Volume
1.47k
114% of avg
P/E Ratio
-14.75
EPS (TTM)
-60
Beta
1.01
Day Range
0.00p - 0.00p
52 Week Range
0.00p885.00p1,500.00p
885.00p
Upcoming Events
Mid-July 2026
Next allocation of shares under the employee incentive plan
4BB
NEUTRAL4basebio Appoints New Executive Chair
The biotechnology company has appointed a new Executive Chair, Dr. Manja Boerman, following an investment by Elevage Medical Technologies.
4BB
NEUTRAL4basebio PLC Announces Major Shareholding Change
The biotechnology company has reported a change in major shareholding, with DELPHI Unternehmensberatung Aktiengesellschaft increasing its stake to over 33%.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
4BB
NEUTRAL4basebio PLC Announces Major Shareholder Holding Change
The biotechnology company has announced a change in the holdings of a major shareholder.
4BB
NEUTRAL4basebio PLC Announces Change in Shareholding
The biotechnology company has announced a change in its major shareholding structure.
4BB
NEUTRAL4basebio Announces Exercise of Employee Share Options
The biotechnology company has announced that two employees have exercised EMI options over 13,000 ordinary shares, raising total proceeds of £15,340.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced a change in major shareholdings.
4BB
NEUTRAL4basebio PLC Announces Major Shareholder Disclosure
The biotechnology company has received a notification of a change in major shareholder holdings.
4BB
NEUTRAL4basebio PLC Reports Doubled DNA Revenues but Widening Losses in 2024 Results
The biotechnology firm doubled its DNA revenues but reported widening losses. Despite securing significant funding and expanding its customer base, the company expects to remain loss-making in 2025.